Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)
WHY TETRA BIO-PHARMA?
- Only pharmaceutical company to have clinical studies for smoked marijuana;
- Company is financially sound, with enough cash to pay for the $1.2Â million Phase III clinical trials of PPP001.
- Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
- Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
- Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
- Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.
Tags: #smallcapstocks, $TSXV, Cannagrow, CSE